These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36444507)

  • 1. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Kumar S; Doshi D
    J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.
    Rajagopalan K; Rashid N; Doshi D
    J Med Econ; 2023; 26(1):769-776. PubMed ID: 37272069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    J Comp Eff Res; 2024 Jul; 13(7):e240038. PubMed ID: 38850129
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.
    Rajagopalan K; Rashid N; Doshi D
    J Comp Eff Res; 2024 Jan; 13(1):e230114. PubMed ID: 38099518
    [No Abstract]   [Full Text] [Related]  

  • 5. Incremental health care resource utilization and costs associated among patients with Parkinson's disease psychosis and incident dementia: An analysis of medicare beneficiaries.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    Int J Geriatr Psychiatry; 2023 Nov; 38(11):e6017. PubMed ID: 37936540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson's Disease Psychosis.
    Rajagopalan K; Rashid N; Yakkala V; Doshi D
    Clinicoecon Outcomes Res; 2024; 16():149-159. PubMed ID: 38495124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Falls and Fractures among Nursing Home Residents Treated with Pimavanserin versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson's Disease Psychosis.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    Drugs Real World Outcomes; 2024 Sep; 11(3):441-449. PubMed ID: 38914856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
    Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotic use and mortality risk in Parkinson disease.
    Pham Nguyen TP; Thibault D; Hamedani AG; Weintraub D; Willis AW
    Parkinsonism Relat Disord; 2022 Oct; 103():17-22. PubMed ID: 36027858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
    Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
    Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
    Sellers J; Darby RR; Farooque A; Claassen DO
    Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden of illness among patients with dementia-related psychosis.
    Frazer M; Abler V; Halpern R; Skoog B; Rashid N
    J Manag Care Spec Pharm; 2021 Mar; 27(3):367-378. PubMed ID: 33645238
    [No Abstract]   [Full Text] [Related]  

  • 19. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.